MARKET

AXGT

AXGT

Axovant Gene Therapies
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.020
+0.050
+1.68%
Closed 16:00 08/07 EDT
OPEN
2.980
PREV CLOSE
2.970
HIGH
3.040
LOW
2.980
VOLUME
195.95K
TURNOVER
--
52 WEEK HIGH
8.08
52 WEEK LOW
1.410
MARKET CAP
121.81M
P/E (TTM)
-1.0080
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AXGT stock price target is 13.57 with a high estimate of 23.00 and a low estimate of 8.00.

EPS

AXGT News

More
AAAPL, FB among premarket gainers
Seeking Alpha · 07/31 12:26
Axovant signs gene therapy supply deal with Oxford Biomedica
Seeking Alpha · 07/31 10:48
Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica for Manufacturing and Supply of AXO-Lenti-PD
NEW YORK and BASEL, Switzerland, July 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, announced today that its subsidiary has signed a three-year C
GlobeNewswire · 07/31 10:30
3 “Strong Buy” Penny Stocks That Could Deliver Massive Returns
Investor focus has landed squarely on the surge in new COVID-19 cases and its threat to economic reopenings, but there’s another possibility being ignored. According to Morgan Stanley equity strategist Mike Wilson, even though the market is expecting economic
TipRanks · 07/13 23:02
Should You Buy Axovant Gene Therapies Ltd. (AXGT)?
Insider Monkey · 07/06 01:46
Why Axovant Gene Therapies (AXGT) Stock Might be a Great Pick
Zacks · 06/24 05:00
Axovant Gene Therapies Q4 EPS $(0.54) Down From $(0.45) YoY
Axovant Gene Therapies (NASDAQ:AXGT) reported quarterly losses of $(0.54) per share. This is a 20 percent decrease over losses of $(0.45) per share from the same period last year.
Benzinga · 06/10 10:03
Axovant Reports Cash Position Of $80.8M As Of Mar. 31; Provides Corporate And Clinical Update
Completed enrollment of cohort 2 of SUNRISE-PD Phase 2 study of AXO-Lenti-PD in Parkinson’s disease, with data from this cohort expected in Q4 2020 Completed enrollment of low-dose cohort of Phase 1/2 clinical
Benzinga · 06/10 10:02

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About AXGT

Axovant Gene Therapies Ltd., formerly Axovant Sciences Ltd., is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. Its AXO-Lenti-PD is an in vivo lentiviral gene therapy investigational product candidate and being developed for the one-time treatment of Parkinson’s disease.
More

Webull offers kinds of Axovant Gene Therapies Ltd stock information, including NASDAQ:AXGT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXGT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AXGT stock methods without spending real money on the virtual paper trading platform.